Ashland Completes Expansion of Viatel Bioresorbable Polymer Manufacturing Site
The expansion will allow Ashland to focus on clinical study projects and commercialization activities.
Ashland announced on March 4, 2021 that it has completed the expansion of its Viatel bioresorbable polymer manufacturing site and has transferred its R&D activities from Dublin, Ireland, to the National Science Park in Mullingar, Ireland.
According to a company press release, Ashland provides more than 70 good manufacturing practice (GMP) grades of lactide/glycolide/caprolactone copolymers within its Viatel portfolio, including a custom-made polymer production unit to meet customer requirements.
“Viatel bioresorbable polymers are used to deliver improved treatment solutions for many chronic diseases,” said Seán McMahon, PhD, business manager, Viatel bioresorbable polymers, Ashland, in the press release. “These materials are the building blocks in extended-release drug formulations, bioresorbable medical devices, and tissue engineering scaffolds. Relocation of R&D to the Mullingar site is critical for our new product development strategy and our ability to solve complex customer challenges with customized chemistry.”
“This facility expansion allows Ashland to focus on serving our customer needs as they pursue clinical studies and prepare for commercialization,” added Dean Ross, global business manager, pharmaceutical specialties, Ashland, in the press release. “We believe the Mullingar facility provides an excellent environment for manufacturing and creative problem-solving.”
Source: Ashland
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
